Quidel reported after the close of the market Thursday that its second quarter revenues fell 12 percent year over year, which the firm attributed to decreased demand for its Sofia and PCR COVID-19 assays, as well as lower demand for influenza products.

2021 ranking features 143 Chinese companies, 122 U.S. companies, and 53 Japanese companies. 6 in vitro diagnostic companies on the list.

Autobio 's revenue was 2.978 billion yuan, while Liferiver reached was 2.052 billion yuan.

Recently, a number of Chinese listed IVD companies released 2020 annual performance report, disclosing their revenue. Driven by the demand of testing products of COVID-19, the performance growth is very gratifying.

Agilent Technologies reported after the close of the market on Thursday that its second quarter 2020 revenue growth was flat year over year. The firm noted that core revenues, which excludes the impact of currency and acquisitions and divest

GenMark Diagnostics reported after the close of the market on Monday a 23 percent increase in second quarter revenues, driven by strong placements of its ePlex analyzer.